Orlistat Reduces Uric Acid in Overweight/Obese Patients With Hyperuricemia

Phase 4 Completed 72 enrolled Shanghai 10th People's Hospital

RandomizedParallel-groupDouble-blindTreatment

Summary

To clarify the uric acid-lowering efficacy of orlistat in overweight/obese patients with hyperuricemia, and to evaluate the safety of orlistat treatment

Timeline

Start: 2022-08-26
Primary completion: 2023-12-01
Completion: 2023-12-01

Publications

Liu S, Lin X, Tao M, Chen Q, Sun H, Han Y, Yang S, Gao Y, Qu S, Chen H. Efficacy and safety of orlistat in male patients with overweight/obesity and hyperuricemia: results of a randomized, double-blind, placebo-controlled trial. Lipids Health Dis. 2024 Mar 11;23(1):77. doi: 10.1186/s12944-024-02047-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orlistat	Small molecule	0.12 g	Oral

Indications

No indication recorded.